Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 274 clinical trials
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS

, donors could undergo a second PB collection within 30 days from the first one. Patients will receive immunosuppressive chemotherapy, fludarabine (Flu) 25 mg/mq/ from day -7 to -3 and cyclophosphamide (Cy

immunosuppressants
fludarabine
cell transplantation
cyclophosphamide
leukapheresis
  • 0 views
  • 03 Feb, 2021
  • 1 location
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

therapeutic option for CLL patients. Their conclusions were that allo-HCT was reasonable for younger CLL patients refractory to fludarabine, relapsing within two years of intensive treatment, or

hematologic malignancy
richter syndrome
ofatumumab
alemtuzumab
anti-cd20 monoclonal antibody
  • 12 views
  • 08 Nov, 2020
  • 2 locations
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

Usually Chronic lymphocytic leukemia (CLL) is a disease of the elderly patients. However, the diagnosis in young patients become more frequently with poor prognosis. The identification of new prognostic factors permits early determination of the high risk population and provide them the therapeutic intensification. Allogeneic transplantation of hematopoietic stem cells …

graft versus host disease
lymphoma
remission
fludarabine
residual tumor
  • 11 views
  • 07 Nov, 2020
  • 1 location
Adoptive Cell Therapy Following a Non-myeloablative Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 (IL-2) has demonstrated reproducible objective response rates of approximately 50 percent in patients with highly advanced, refractory metastatic melanoma. Recent developments in theTIL ACT procedure facilitate the use of a reduced-intensity, non-myeloablative, lympho-depleting preparative …

  • 10 views
  • 22 Jan, 2021
  • 1 location
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia

The allograft of marrow in its technique of reference (myélo-ablative (MA) condition by cyclophosphamide and total body irradiation (TBI) with strong amounts) therapeutic is recognized acute myeloid leukaemia (AML) of the adult for the patients of less than 55 years, because it offers chances of cure higher than chemotherapy or …

remission
idarubicin
secondary acute myeloid leukemia
daunorubicin
cyclophosphamide
  • 18 views
  • 07 Nov, 2020
  • 1 location
CD19-CAR-T in B-cell Malignancies Patients

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-CAR-T cells in patients with refractory and relapsed B-cell malignancies.

  • 2 views
  • 24 Jan, 2021
  • 1 location
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-STAR-T cells in patients with refractory and relapsed B-cell malignancies (such as NHL and ALL ).

  • 0 views
  • 25 Jan, 2021
  • 1 location
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression …

bone marrow transplant
anemia severe
immunosuppression
cyclophosphamide
aplastic anemia
  • 20 views
  • 05 Mar, 2021
  • 2 locations
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A in adults with r/r MM.

  • 0 views
  • 28 Jan, 2021
  • 2 locations
Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome

  • 0 views
  • 25 Jan, 2021
  • 1 location